Phentermine 및 Phendimetrazine으로 유발된 정신병적 장애 및 양극성 장애 증례군 연구
Phentermine and Phendimetrazine-Induced Psychotic Disorder and Bipolar Disorder: A Case Series
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives Recently, weight loss has emerged as a national concern in South Korea, and this has resulted in an increase in the frequency of use of central nervous system (CNS)-stimulating appetite suppressants. This study aimed to collect cases of psychotic disorders and bipolar disorders triggered by phentermine and phendimetrazine and explore the clinical features and courses. Methods In this retrospective study, we analyzed the electronic medical records of patients and selected eight patients who developed psychotic symptoms and manic symptoms for the first time after taking phentermine and phendimetrazine. All cases were reviewed, and their clinical features and course were summarized. Results All eight patients developed psychotic symptoms, and one had accompanying manic symptoms. The final diagnosis was appetite-suppressant-induced psychotic disorder in four patients, schizophrenia in three, and appetite-suppressant-induced bipolar disorder in one. In addition, three patients were diagnosed as having substance-use disorder. The key psychotic symptoms of these patients were hallucinations and paranoia. Conclusions These case findings suggest that phentermine and phendimetrazine can cause psychotic disorder, bipolar disorder, or substance use disorder and that medical professionals and the public should practice caution when prescribing and using these drugs.
Abstract
Objectives Recently, weight loss has emerged as a national concern in South Korea, and this has resulted in an increase in the frequency of use of central nervous system (CNS)-stimulating appetite suppressants. This study aimed to collect cases of psychotic disorders and bipolar disorders triggered by phentermine and phendimetrazine and explore the clinical features and courses. Methods In this retrospective study, we analyzed the electronic medical records of patients and selected eight patients who developed psychotic symptoms and manic symptoms for the first time after taking phentermine and phendimetrazine. All cases were reviewed, and their clinical features and course were summarized. Results All eight patients developed psychotic symptoms, and one had accompanying manic symptoms. The final diagnosis was appetite-suppressant-induced psychotic disorder in four patients, schizophrenia in three, and appetite-suppressant-induced bipolar disorder in one. In addition, three patients were diagnosed as having substance-use disorder. The key psychotic symptoms of these patients were hallucinations and paranoia. Conclusions These case findings suggest that phentermine and phendimetrazine can cause psychotic disorder, bipolar disorder, or substance use disorder and that medical professionals and the public should practice caution when prescribing and using these drugs.
참고문헌 (33)
- World Health Organization, "The Asia-Pacific Perspective: Redefining Obesity and Is Treatment", Health Communications Australia, ~ (2000)
- Korea Disease Control and Prevention Agency, "Korea Health Statistics 2019: Korea National Health and Nutrition Examination Survey (KNHANES VIII-1)" (2020), Korea Disease Control and Prevention Agency
- "Kosis.kr" (2021)[URL]
- 서미혜, "Prevalence of Obesity and Incidence of Obesity-Related Comorbidities in Koreans Based on National Health Insurance Service Health Checkup Data 2006-2015 (J Obes Metab Syndr 2018;27:46-52)", Journal of Obesity & Metabolic Syndrome, 27(3), pp.198~199 (2018), 대한비만학회
- 서미혜, "2018 Korean Society for the Study of Obesity Guideline for the Management of Obesity in Korea", Journal of Obesity & Metabolic Syndrome, 28(1), pp.40~45 (2019), 대한비만학회[DOI]
- Bray GA, "The science of obesity management : an endocrine society scientific statement", Endocr Rev, 39, pp.79~132 (2018)
- 조선진, "중추신경흥분성 식욕억제제 사용의 부작용에 관한 신속 체계적 문헌고찰: 의존 및 정신병 중심으로", 중독정신의학, 25(2), pp.45~57 (2021), 한국중독정신의학회
- Rothman RB, "Appetite suppressants, cardiac valve disease and combination pharmacotherapy", Am J Ther, 16, pp.354~364 (2009)
- 김경곤, "국내에서 현재 장기간 사용목적으로 선택할 수 있는 비만 치료약제의 작용기전과 임상응용", 대한의사협회지, 62(11), pp.588~597 (2019), 대한의사협회
- Bramness JG, "Amphetamine-induced psychosis--a separate diagnostic entity or primary psychosis triggered in the vulnerable?", BMC Psychiatry, 12, pp.221~ (2012)
- Rubin RT, "Acute psychotic reaction following ingestion of phentermine", Am J Psychiatry, 120, pp.1124~1125 (1964)
- Homola J, "Combination of venlafaxine and phentermine", topiramate induced psychosis : a case report, 2018, pp.8, 95~99
- Alexander J, "Phentermine(Duromine)precipitated psychosis", Aust N Z J Psychiatry, 45, pp.684~685 (2011)
- Lee SH, "Schizophreniform-like psychotic disorder induced by phentermine: a case report", Zhonghua Yi Xue Za Zhi(Taipei), 61, pp.44~47 (1998)
- Cleare AJ, "Phentermine, psychosis, and family history", J Clin Psychopharmacol, 16, pp.470~471 (1996)
- Devan GS, "Phentermine and psychosis", Br J Psychiatry, 156, pp.442~443 (1990)
- Hoffman BF, "Diet pill psychosis : follow-up after 6 years", Can Med Assoc J, 129, pp.1077~1078 (1983)
- Hoffman BF, "Diet pill psychosis", Can Med Assoc J, 116, pp.351~355 (1977)
- Raison CL, "Psychotic mania associated with fenfluramine and phentermine use", Am J Psychiatry, 154, pp.711~ (1997)
- Bagri S, "Delirium with manic symptoms induced by diet pills", J Clin Psychiatry, 59, pp.83~ (1998)
- Zimmer JE, "Bipolar depression associated with fenfluramine and phentermine", J Clin Psychiatry, 59, pp.383~384 (1998)
- Kim SH, "A case of organic hallucinous following phendimetrazine(Fringar@)abuse", J Korean Neuropsychiatr Assoc, 31, pp.1119~1122 (1992)
- 이종민, "Phendimetrazine 사용으로 유발된 정신증적 장애 2예", 대한정신약물학회지, 21(2), pp.95~98 (2010), 대한정신약물학회
- 윤지애, "Phendimetrazine 사용으로 유발된 정신증적 장애 및 의존 1예", 신경정신의학, 52(5), pp.402~405 (2013), 대한신경정신의학회
- 곽숙영, "식욕억제제 Phentermine, Phendimetrazine으로 유발된 정신병적 장애 증례군 연구", 생물정신의학, 24(3), pp.134~141 (2017), 대한생물정신의학회[DOI]
- Hyun-Sic Jo, "Recurrent Psychosis after Phentermine Administration in a Young Female: A Case Report", Clinical Psychopharmacology and Neuroscience, 17(1), pp.130~133 (2019), 대한정신약물학회[DOI]
- Starzer MSK, "Rates and predictors of conversion to schizophrenia or bipolar disorder following substance-induced psychosis", Am J Psychiatry, 175, pp.343~350 (2018)
- Clinical Psychiatry, "Kaplan & Sadock’s Synopsis of Psychiatry:Behavioral Sciences", pp.2015, Sadock BJ
- Baumann MH, "Effects of phentermine and fenfluramine on extracellular dopamine and serotonin in rat nucleus accumbens : therapeutic implications", Synapse, 36, pp.102~113 (2000)
- Solis E Jr, "Dissociable effects of the prodrug phendimetrazine and its metabolite phenmetrazine at dopamine transporters", Sci Rep, 6, pp.31385~ (2016)
- 안호영, "Phentermine, Sibutramine and Affective Disorders", Clinical Psychopharmacology and Neuroscience, 11(1), pp.7~12 (2013), 대한정신약물학회
- Niemi-Pynttäri JA, "Substance-induced psychoses converting into schizophrenia : a register-based study of 18, 478 Finnish inpatient cases", J Clin Psychiatry, 74, pp.e94~e99 (2013)
- Chen WL, "The epidemiology and progression time from transient to permanent psychiatric disorders of substance-induced psychosis in Taiwan", Addict Behav, 47, pp.1~4 (2015)